Last reviewed · How we verify
Dihydroartemisinin and piperaquine
At a glance
| Generic name | Dihydroartemisinin and piperaquine |
|---|---|
| Also known as | Eurartesim |
| Sponsor | INDEPTH Network |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults (PHASE1)
- Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria (PHASE4)
- Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana (NA)
- Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated Malaria in Western Kenya
- Intermittent Preventive Treatment of Malaria in School-age Children to Decrease Community Transmission (PHASE4)
- Perennial Malaria Chemoprevention in the Malaria Vaccine Era (PHASE4)
- Mass Vaccine and Drug Administration, Bangladesh (PHASE4)
- Pharmacokinetics and Pharmacodynamics of the Gametocytocidal and Post-treatment Chemoprotective Effects of Antimalarials (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dihydroartemisinin and piperaquine CI brief — competitive landscape report
- Dihydroartemisinin and piperaquine updates RSS · CI watch RSS
- INDEPTH Network portfolio CI